A 5 Year Follow-up of Patients Who Were Previously Enrolled Into an Advagraf Trial Following a Liver or Kidney Transplant
NCT ID: NCT02057484
Last Updated: 2024-10-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
2300 participants
OBSERVATIONAL
2014-03-03
2017-10-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prospective Study to Measure Vascular Parameters (Ancillary Study of ADEQUATE)
NCT02154854
Study to Evaluate the Safety and Efficacy of Advagraf vs Prograf in Kidney Transplantation Patients 1 Month After the Transplantation
NCT01742624
A Multicenter Study in Liver Transplant Patients Converted From Prograf® to Advagraf® During the First Post-transplantation Year
NCT02143479
Study to Compare the Pharmacokinetics of Tacrolimus in Adult Transplant Recipients Treated With Advagraf® or Prograf®
NCT01332201
To Evaluate the Efficacy and Safety of ADVAGRAF® After Treatment With a Tacrolimus in New Liver Transplant Recipients
NCT04761731
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study will follow up adult patients who were previously enrolled in an Advagraf trial after they have had a liver or kidney transplant. The information collected for this study will be information that the patient's doctor will normally collect when he/she sees the patient for their regular check-ups. Information will be collected once a year for a period of 5 years from when the patient received their new organ transplant. It is hoped that patient information collected during the study will provide prescribers with useful information in treatment of organ transplant patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Organ transplant patients treated with Advagraf
To evaluate long-term graft survival in patients treated with Advagraf
Tacrolimus
oral
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tacrolimus
oral
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* DIAMOND - PMR-EC-1106
* ADVANCE - PMR-EC-1211
* ADHERE - PMR-EC-1212
* Or, any potential new Astellas-sponsored Advagraf trial
* Assigned to treatment with Advagraf in one of the selected Astellas sponsored clinical trials and received a kidney or liver organ transplant.
NOTE: The primary objective is to study long-term graft survival in patients currently or previously treated with Advagraf. Therefore patients do not have to be currently receiving Advagraf to be included, nor do they have to have completed a previous Astellas clinical trial.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astellas Pharma Europe Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Astellas Pharma Europe Ltd.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site AT43001
Innsbruck, , Austria
Site AT43003
Linz, , Austria
Site AT43002
Vienna, , Austria
Site BY37501
Minsk, , Belarus
Site BE32007
Brussels, Brussels Capital, Belgium
Site BE32002
Brussels, , Belgium
Site BE32001
Ghent, , Belgium
Site BE32003
Leuven, , Belgium
Site BE32005
Leuven, , Belgium
Site BE32008
Liège, , Belgium
Site BE32009
Liège, , Belgium
Site CA15001
Halifax, Nova Scotia, Canada
Site CA15003
Montreal, Quebec, Canada
Site CZ42006
Brno, , Czechia
Site CZ42004
Hradec Králové, , Czechia
Site CZ42003
Olomouc, , Czechia
Site CZ42005
Ostrava, , Czechia
Site CZ42001
Prague, , Czechia
Site CZ42002
Prague, , Czechia
Site EE37201
Tartu, , Estonia
Site FI35801
Helsinki, , Finland
Site FI35802
Helsinki, , Finland
Site FR33020
Angers, , France
Site FR33007
Besançon, , France
Site FR33012
Bordeaux, , France
Site FR33025
Brest, , France
Site FR33027
Clermont-Ferrand, , France
Site FR33003
Clichy, Paris, , France
Site FR33001
Créteil, , France
Site FR33029
Créteil, , France
Site FR33032
Dijon, , France
Site FR33026
Le Kremlin-Bicêtre, , France
Site FR33018
Limoges, , France
Site FR33011
Marseille, , France
Site FR33014
Montpellier, , France
Site FR33023
Nantes, , France
Site FR33004
Nice, , France
Site FR33015
Nice, , France
Site FR33008
Paris, , France
Site FR33010
Paris, , France
Site FR33031
Paris, , France
Site FR33019
Paris, , France
Site FR33024
Rouen, , France
Site FR33022
Saint-Etienne, , France
Site FR33017
Strasbourg, , France
Site FR33034
Toulouse, , France
Site FR33009
Tours, , France
Site FR33030
Tours, , France
Site FR33028
Vandœuvre-lès-Nancy, , France
Site FR33002
Villejuif, , France
Site DE49011
Aachen, , Germany
Site DE49004
Berlin, , Germany
Site DE49019
Bochum, , Germany
Site DE49013
Düsseldorf, , Germany
Site DE49030
Essen, , Germany
Site DE49001
Frankfurt am Main, , Germany
Site DE49014
Halle, , Germany
Site DE49022
Hannoversch Münden, , Germany
Site DE49005
Hanover, , Germany
Site DE49018
Hanover, , Germany
Site DE49008
Jena, , Germany
Site DE49015
Kaiserslautern, , Germany
Site DE49002
Kiel, , Germany
Site DE49027
Mannheim, , Germany
Site DE49025
Munich, , Germany
Site DE49016
Munich, , Germany
Site DE49010
Regensburg, , Germany
Site DE49017
Rostock, , Germany
Site DE49006
Tübingen, , Germany
Site HU36001
Budapest, , Hungary
Site HU36003
Debrecen, , Hungary
Site HU36002
Szeged, , Hungary
Site IE35301
Dublin, , Ireland
Site IT39015
Ancona, , Italy
Site IT39003
Bergamo, , Italy
Site IT39005
Bologna, , Italy
Site IT39013
Bologna, , Italy
Site IT39006
Genova, , Italy
Site IT39014
L’Aquila, , Italy
Site IT39012
Milan, , Italy
Site IT39009
Milan, , Italy
Site IT39008
Naples, , Italy
Site IT39002
Padua, , Italy
Site IT39010
Padua, , Italy
Site IT39016
Palermo, , Italy
Site IT39004
Rome, , Italy
Site IT39020
Rome, , Italy
Site IT39017
Salerno, , Italy
Site IT39019
Siena, , Italy
Site IT39021
Treviso, , Italy
Site IT39001
Udine, , Italy
Site IT39011
Vicenza, , Italy
Site LV37101
Riga, , Latvia
Site NL31001
Maastricht, , Netherlands
Site PL48003
Gdansk, , Poland
Site PL48006
Katowice, , Poland
Site PL48005
Lodz, , Poland
Site PL48007
Poznan, , Poland
Site PL48004
Szczecin, , Poland
Site PL48001
Warsaw, , Poland
Site PT35102
Lisbon, , Portugal
Site RO40001
Bucharest, , Romania
Site RO40003
Bucharest, , Romania
Site RU70014
Kemerovo, , Russia
Site RU70005
Moscow, , Russia
Site RU70002
Moscow, , Russia
Site RU70004
Moscow, , Russia
Site RU70007
Moscow, , Russia
Site RU70010
Omsk, , Russia
Site RU70011
Volzhskiy, , Russia
Site RU70013
Volzhskiy, , Russia
Site RU70012
Yekaterinburg, , Russia
Site SK42101
Banská Bystrica, , Slovakia
Site SK42102
Bratislava, , Slovakia
Site KR82007
Busan, , South Korea
Site KR82006
Daegu, , South Korea
Site KR82002
Seoul, , South Korea
Site KR82005
Seoul, , South Korea
Site KR82001
Seoul, , South Korea
Site ES34001
L'Hospitalet de Llobregat, Barcelona, Spain
Site ES34019
Barakaldo, Vizcaya, Spain
Site ES34005
A Coruña, , Spain
Site ES34017
Alicante, , Spain
Site ES34012
Badalona-Barcelona, , Spain
Site ES34004
Barcelona, , Spain
Site ES34011
Barcelona, , Spain
Site ES34003
Barcelona, , Spain
Site ES34010
Córdoba, , Spain
Site ES34018
L'Hospitalet de Llobregat, , Spain
Site ES34006
Madrid, , Spain
Site ES34013
Madrid, , Spain
Site ES34015
Madrid, , Spain
Site ES34009
Santa Cruz de Tenerife, , Spain
Site ES34020
Santander, , Spain
Site ES34014
Seville, , Spain
Site ES34021
Valencia, , Spain
Site ES34016
Valladolid, , Spain
Site ES34007
Zaragoza, , Spain
Site SE46001
Gothenburg, , Sweden
Site SE46002
Stockholm, , Sweden
Site SE46004
Uppsala, , Sweden
Site CH41002
Bern, , Switzerland
Site GB44001
Birmingham, , United Kingdom
Site GB44003
Leeds, , United Kingdom
Site GB44002
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Link to results on the Astellas Clinical Study Results Web site
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PMR-EC-1213
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.